MYOC基因p.Gln368Ter变异的外显率及其与青光眼关联的人群与登记研究
结果显示该变异对原发性开角型青光眼OR为6.76,对晚期青光眼OR达12.16,人群中外显率约7.6%至30.8%,而登记研究中晚期青光眼外显率高达56.1%。
要点
- MYOC p.Gln368Ter变异对原发性开角型青光眼OR为6.76,对晚期青光眼OR高达12.16。
- 英国生物银行中该变异对青光眼外显率7.6%,对高眼压24.3%,两者合并30.8%。
- 澳大利亚登记研究中青光眼外显率56.1%,含疑似青光眼达69.5%。
核心结论
- MYOC p.Gln368Ter变异对晚期青光眼具有非常高的风险效应量,对非晚期青光眼和高眼压风险较低。
- 普通人群样本中65岁及以上携带者约50%患有青光眼或高眼压,澳大利亚登记研究中的患病率更高。
研究设计与样本
- 青光眼病例依据ICD-9和ICD-10诊断及自报问卷定义,变异携带者通过基因型插补识别。
- 澳大利亚登记研究由眼科临床医生转诊的病例组成,样本经直接测序或插补确定基因型。
主要发现
- 英国生物银行中MYOC p.Gln368Ter次要等位基因频率为1/786(0.13%)。
- 原发性开角型青光眼OR为6.76(95%CI 4.05-11.29),青光眼(含自报和未指定)OR为4.40(95%CI 3.38-5.71),高眼压OR为3.56(95%CI 2.53-4.92),高眼压与青光眼合并OR为4.18(95%CI 3.05-5.67)。
- 澳大利亚登记研究中晚期青光眼OR为12.16(95%CI 6.34-24.97),非晚期青光眼OR为3.97(95%CI 1.55-9.75)。
关键数值与推荐
- 英国生物银行中青光眼外显率7.6%,高眼压外显率24.3%,高眼压与青光眼合并外显率30.8%。
- 澳大利亚登记研究中青光眼外显率56.1%,青光眼或疑似青光眼外显率69.5%。
临床怎么用
- 检测到MYOC p.Gln368Ter变异者应警惕晚期青光眼高风险,需加强青光眼筛查与随访。
- 该变异携带者中高眼压也较常见,应同时监测眼压。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The p.Gln368Ter (rs74315329) risk allele in the myocilin gene (MYOC) was initially reported to have high penetrance in glaucoma registry-based studies, but much lower estimates were recently obtained from population-based studies. We investigated this disparity using data from Australia and the United Kingdom. OBJECTIVES: To examine the penetrance and effect size of the MYOC p.Gln368Ter variant with glaucoma and ocular hypertension (OHT). DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study within the UK Biobank (UKBB) included participants of white British ancestry. Glaucoma cases were defined by International Classification of Diseases, Ninth Revision (ICD-9) and Tenth Revision (ICD-10) diagnoses and self-reported questionnaires. Carriers of the MYOC p.Gln368Ter variant were identified using genotype imputation from arrays. In contrast, 2 Australian registry-based studies, the Australian and New Zealand Registry of Advanced Glaucoma and the Glaucoma Inheritance Study in Tasmania, ascertained glaucoma cases referred by eye care clinicians, with historic control participants recruited from other Australian studies. Samples were either directly sequenced or had genotypes determined by imputation (for the Australian registry and historic control participants). Recruitment to the UKBB occurred between 2006 and 2010, and data analysis occurred from September 2017 to July 2018. MAIN OUTCOMES AND MEASURES: The penetrance and odds ratio (OR) were estimated for the MYOC p.Gln368Ter variants in participants with glaucoma and OHT. RESULTS: A total of 411 337 UKBB participants of white British ancestry (mean [SD] age, 56.6 [8.0] years) were included, plus 3071 Australian registry and 6750 historic control participants. In the UKBB, the minor allele frequency of the MYOC p.Gln368Ter variant was 1 in 786 individuals (0.13%). The odds ratio of p.Gln368Ter in patients with primary open-angle glaucoma (POAG) was 6.76 (95% CI, 4.05-11.29); glaucoma (POAG, self-reported glaucoma, and unspecified glaucoma), 4.40 (95% CI, 3.38-5.71); OHT, 3.56 (95% CI, 2.53-4.92); and OHT and glaucoma combined, 4.18 (95% CI, 3.05-5.67). The penetrance of the MYOC p.Gln368Ter variant was 7.6% in patients with glaucoma, 24.3% in patients with OHT, and 30.8% in patients with OHT and glaucoma combined. In the Australian registry studies, the odds of MYOC p.Gln368Ter variant were 12.16 (95% CI, 6.34-24.97) in patients with advanced glaucoma and 3.97 (95% CI, 1.55-9.75) in those with nonadvanced glaucoma; the penetrance of glaucoma was 56.1%, and penetrance in those considered to have glaucoma or be glaucoma suspects was 69.5%. CONCLUSIONS AND RELEVANCE: The MYOC p.Gln368Ter variant confers a very high-risk effect size for advanced glaucoma; the risk is lower in nonadvanced glaucoma and OHT. In the general population sample, approximately 50% of MYOC p.Gln368Ter carriers 65 years and older had glaucoma or OHT, with higher prevalence in the Australian registry studies.
引用
- Han X, Souzeau E, Ong JS, et al. Myocilin Gene Gln368Ter Variant Penetrance and Association With Glaucoma in Population-Based and Registry-Based Studies. JAMA Ophthalmol. 2019. PMID: 30267046. doi:10.1001/jamaophthalmol.2018.4477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。